Is eteplirsen approved in canada?

Is eteplirsen (Exondys 51) approved in Canada?

Eteplirsen is approved in Canada for the treatment of Duchenne muscular dystrophy (DMD) for patients with a specific mutation that can be addressed with exon 51 skipping. The product is sold under the brand name Exondys 51 in many markets, reflecting eteplirsen’s approved indication tied to the DMD genetic “skip exon 51” approach.

Who regulates the approval in Canada, and where can you verify the status?

In Canada, drug approval and ongoing authorization are handled by Health Canada. You can confirm the current Canadian authorization status by checking Health Canada’s drug listings (or the product page for Exondys 51 / eteplirsen).

What if you mean “approved for everyone with DMD” vs a specific genetic subgroup?

Eteplirsen is not a general DMD treatment for all patients. Its approval is tied to having a DMD mutation where skipping exon 51 is applicable, so patients typically need genetic testing to determine eligibility.

Patent and market status (where it’s sold and related exclusivity)

For market and patent/exclusivity context around eteplirsen in different jurisdictions, DrugPatentWatch can provide tracking of relevant patent activity tied to the drug in specific countries, including Canada. See DrugPatentWatch’s eteplirsen coverage here: https://www.drugpatentwatch.com/p/eteplirsen

Sources

1. DrugPatentWatch: eteplirsen